USPTO serial 85872878
NEUROPRO
Reviewed by CopyMark Law Group
Status 603
- Filing date
- Status date
- Registration date
- —
- Examiner
- PHILLIPS, WENDELL SHARMAN
- Law office
- TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEUROPRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Vancouver, BC, CA
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Herbal supplements containing ginseng and ginsenocides, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginsenocides, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginsenocides and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng extract, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng extract and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; medical food supplements in powdered, liquid and tablet form for the prevention and treatment of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis; medical food for the treatment of spinal cord injury and brain injury; medical food supplements in powdered, liquid and tablet form; medical food supplements in powdered, liquid and tablet form for use in the dietary management of patients with neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, spinal cord injury, and brain injury; ginseng, ginsenocides and omega-3 fatty acids for the dietary management of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, spinal cord injury, and brain injury | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 2, 2014 | MAB3 | ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL | — |
| Nov 25, 2014 | ABN3 | ABANDONMENT - AFTER EX PARTE APPEAL | — |
| Nov 25, 2014 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Oct 16, 2014 | EXFB | EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF | — |
| Jul 22, 2014 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 22, 2014 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 22, 2014 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Jul 15, 2014 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Jul 15, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 14, 2014 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jul 14, 2014 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jul 14, 2014 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jul 11, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 10, 2014 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jul 10, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 10, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 10, 2014 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jan 14, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 14, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 14, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 24, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 23, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 23, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 24, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 16, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Mar 15, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 14, 2013 | NWAP | NEW APPLICATION ENTERED | — |